Literature DB >> 20930707

Adiponectin and hypertension.

Koji Ohashi1, Noriyuki Ouchi, Yuji Matsuzawa.   

Abstract

Adipose tissue secretes a variety of bioactive molecules, also known as adipocytokines or adipokines. Obesity, in particular, visceral fat accumulation, is implicated in the dysregulated secretion of adipocytokines, which can contribute to the development of metabolic syndrome and cardiovascular diseases. Adiponectin is an adipocytokine that is exclusively secreted from adipose tissue, but its plasma levels are reduced in obese subjects, especially those with visceral fat accumulation. Adiponectin has a variety of protective properties against obesity-linked complications, such as hypertension, metabolic dysfunction, atherosclerosis, and ischemic heart disease. Adiponectin exerts the beneficial effects on vascular disorders by directly affecting components of vascular tissue. This review will discuss clinical and experimental findings that examine the role of adiponectin in regulation of hypertension and vascular function.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20930707     DOI: 10.1038/ajh.2010.216

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  42 in total

1.  Adipose tissue as regulator of vascular tone.

Authors:  Charlotte Boydens; Nele Maenhaut; Bart Pauwels; Kelly Decaluwé; Johan Van de Voorde
Journal:  Curr Hypertens Rep       Date:  2012-06       Impact factor: 5.369

Review 2.  Adipokines protecting CKD.

Authors:  Satoshi Miyamoto; Kumar Sharma
Journal:  Nephrol Dial Transplant       Date:  2013-11       Impact factor: 5.992

3.  Chronic effects of centrally administered adiponectin on appetite, metabolism and blood pressure regulation in normotensive and hypertensive rats.

Authors:  Mirian Bassi; Jussara M do Carmo; John E Hall; Alexandre A da Silva
Journal:  Peptides       Date:  2012-06-27       Impact factor: 3.750

Review 4.  Perivascular adipose tissue: more than just structural support.

Authors:  Theodora Szasz; R Clinton Webb
Journal:  Clin Sci (Lond)       Date:  2012-01       Impact factor: 6.124

5.  Adiponectin and metabolic syndrome in a Tunisian population.

Authors:  Samir Ben Ali; Riadh Jemaa; Bouchra Ftouhi; Amani Kallel; Moncef Feki; Hedia Slimene; Naziha Kaabachi
Journal:  Inflammation       Date:  2012-06       Impact factor: 4.092

Review 6.  The role of adiponectin in endothelial dysfunction and hypertension.

Authors:  Edward Rojas; Daloha Rodríguez-Molina; Peter Bolli; Zafar H Israili; Judith Faría; Enzamaría Fidilio; Valmore Bermúdez; Manuel Velasco
Journal:  Curr Hypertens Rep       Date:  2014-08       Impact factor: 5.369

Review 7.  Mechanisms of obesity-induced gastrointestinal neoplasia.

Authors:  José O Alemán; Peter R Holt; Leonardo H Eusebi; Luigi Ricciardiello; Kavish Patidar; Arun J Sanyal
Journal:  Gastroenterology       Date:  2013-12-06       Impact factor: 22.682

Review 8.  Obesity, kidney dysfunction and hypertension: mechanistic links.

Authors:  John E Hall; Jussara M do Carmo; Alexandre A da Silva; Zhen Wang; Michael E Hall
Journal:  Nat Rev Nephrol       Date:  2019-06       Impact factor: 28.314

9.  A study of adiponectin in children with diabetes mellitus.

Authors:  Basma A Ali; Doaa M Mahrous; Ahlam M Abdallah; Mina Fikri
Journal:  Sultan Qaboos Univ Med J       Date:  2013-05-09

10.  High adiponectin levels fail to protect against the risk of hypertension and, in women, against coronary disease: involvement in autoimmunity?

Authors:  Altan Onat; Mesut Aydın; Günay Can; Bayram Köroğlu; Ahmet Karagöz; Servet Altay
Journal:  World J Diabetes       Date:  2013-10-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.